Identification of novel genetic markers of breast cancer survival

Journal of the National Cancer Institute

Volumn 107, Issue 5, 2015, Pages

  Guo, Qi ^a   Schmidt, Marjanka K ^b   Kraft, Peter ^c   Canisius, Sander ^b   Chen, Constance ^c   Khan, Sofia ^d   Tyrer, Jonathan ^a   Bolla, Manjeet K ^e   Wang, Qin ^e   Dennis, Joe ^e   Michailidou, Kyriaki ^e   Lush, Michael ^e   Kar, Siddhartha ^e   Beesley, Jonathan ^f   Dunning, Alison M ^a   Shah, Mitul ^a   Czene, Kamila ^g   Darabi, Hatef ^g   Eriksson, Mikael ^g   Lambrechts, Diether ^h,i   Weltens, Caroline ^j   Leunen, Karin ^j   Bojesen, Stig E ^k,l   Nordestgaard, Børge G ^k,l   Nielsen, Sune F ^k   Flyger, Henrik ^k   Chang Claude, Jenny ^m   Rudolph, Anja ^m   Seibold, Petra ^m   Flesch Janys, Dieter ⁿ   Blomqvist, Carl ^o   Aittomäki, Kristiina ^o   Fagerholm, Rainer ^d   Muranen, Taru A ^d   Couch, Fergus J ^p   Olson, Janet E ^p   Vachon, Celine ^p   Andrulis, Irene L ^q,r   Knight, Julia A ^r,s   Glendon, Gord ^r   Mulligan, Anna Marie ^q,t   Broeks, Annegien ^b   Hogervorst, Frans B ^b   Haiman, Christopher A ^u   Henderson, Brian E ^u   Schumacher, Fredrick ^u   Le Marchand, Loic ^v   Hopper, John L ^w   Tsimiklis, Helen ^x   Apicella, Carmel ^w   Southey, Melissa C ^x   Cox, Angela ^y   Cross, Simon S ^z   Reed, Malcolm W R ^y   Giles, Graham G ^w,aa   Milne, Roger L ^w,aa   McLean, Catriona ^ab   Winqvist, Robert ^ac   Pylkäs, Katri ^ad   Jukkola Vuorinen, Arja ^ae   Grip, Mervi ^ae   Hooning, Maartje J ^af   Hollestelle, Antoinette ^af   Martens, John W M ^af   Van Den Ouweland, Ans M W ^af   Marme, Federik ^ag   Schneeweiss, Andreas ^ag   Yang, Rongxi ^ag   Burwinkel, Barbara ^m,ag   Figueroa, Jonine ^ah   Chanock, Stephen J ^ah,ai   Lissowska, Jolanta ^aj   Sawyer, Elinor J ^ak   Tomlinson, Ian ^al   Kerin, Michael J ^am   Miller, Nicola ^am   Brenner, Hermann ^m   Dieffenbach, Aida Karina ^m   Arndt, Volker ^m   Holleczek, Bernd ^an   Mannermaa, Arto ^ao   Kataja, Vesa ^ao,ap   Kosma, Veli Matti ^ao   Hartikainen, Jaana M ^ao   Li, Jingmei ^a   Brand, Judith S ^a   Humphreys, Keith ^g   Devilee, Peter ^ap   Tollenaar, Rob A E M ^aq   Seynaeve, Caroline ^aq   Radice, Paolo ^ar   Peterlongo, Paolo ^as   Bonanni, Bernardo ^at   Mariani, Paolo ^as,au   Fasching, Peter A ^av,aw   Beckmann, Matthias W ^aw   Hein, Alexander ^aw   Ekici, Arif B ^ax   Chenevix Trench, Georgia ^f   Balleine, Rosemary ^ax,ay   Phillips, Kelly Anne ^az,ba   Benitez, Javier ^az,bb   Zamora, M Pilar ^bc   Arias Perez, Jose Ignacio ^bd   Menéndez, Primitiva ^be   Jakubowska, Anna ^be   Lubinski, Jan ^be   Jaworska Bieniek, Katarzyna ^be   Durda, Katarzyna ^be   Hamann, Ute ^bf   Kabisch, Maria ^bf   Ulmer, Hans Ulrich ^m   Rüdiger, Thomas ^bg   Margolin, Sara ^bh   Kristensen, Vessela ^g,bi   Nord, Silje ^g,bi   Evans, D Gareth ^bj   Abraham, Jean E ^a,bk,bl   Earl, Helena M ^bk,bl   Hiller, Louise ^bm   Dunn, Janet A ^bm   Bowden, Sarah ^bn   Berg, Christine ^bo   Campa, Daniele ^m,ah   Diver, W Ryan ^bp   Gapstur, Susan M ^bp   Gaudet, Mia M ^bp   Hankinson, Susan E ^bq,br   Hoover, Robert N ^bs   Hüsing, Anika ^m   Kaaks, Rudolf ^m   Machiela, Mitchell J ^bs   Willett, Walter ^ah   Barrdahl, Myrto ^m   Canzian, Federico ^c   Chin, Suet Feung ^m   Caldas, Carlos ^bk,bl   Hunter, David J ^c   Lindstrom, Sara ^c   García Closas, Montserrat ^bu   Hall, Per ^g   Easton, Douglas F ^a,e   Eccles, Diana M ^bt   Rahman, Nazneen ^bu   Nevanlinna, Heli ^d   Pharoah, Paul D P ^a,e   more..

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^g KAROLINSKA INSTITUTE   (Sweden)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^l UNIVERSITY OF COPENHAGEN   (Denmark)

^m GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^o HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^p MAYO CLINIC   (United States)

^q UNIVERSITY OF TORONTO   (Canada)

^r MOUNT SINAI HOSPITAL   (Canada)

^s UNIVERSITY OF TORONTO   (Canada)

^t UNIVERSITY HEALTH NETWORK   (Canada)

^u UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^v UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^w UNIVERSITY OF MELBOURNE   (Australia)

^x UNIVERSITY OF MELBOURNE   (Australia)

^y UNIVERSITY OF SHEFFIELD   (United Kingdom)

^z UNIVERSITY OF SHEFFIELD   (United Kingdom)

^aa CANCER EPIDEMIOLOGY CENTRE   (Australia)

^ab ALFRED HOSPITAL   (Australia)

^ac UNIVERSITY OF OULU   (Finland)

^ad Northern Finland Laboratory Centre NordLab Oulu   (Finland)

^ae OULU UNIVERSITY HOSPITAL   (Finland)

^af ERASMUS MC CANCER INSTITUTE   (Netherlands)

^ag UNIVERSITY OF HEIDELBERG   (Germany)

^ah NATIONAL CANCER INSTITUTE   (United States)

^ai FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^aj INSTITUTE OF ONCOLOGY   (Poland)

^ak The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^al UNIVERSITY OF OXFORD   (United Kingdom)

^am UNIVERSITY HOSPITAL GALWAY   (Ireland)

^an Saarland Cancer Registry   (Germany)

^ao KUOPIO UNIVERSITY HOSPITAL   (Finland)

^ap UNIVERSITY OF EASTERN FINLAND   (Finland)

^aq LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^ar ERASMUS MEDICAL CENTER   (Netherlands)

^as NATIONAL CANCER INSTITUTE   (Italy)

^at FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^au EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^av Friedrich Alexander University Erlangen Nuremberg ^*  (Italy)

^aw UNIVERSITY OF CALIFORNIA   (United States)

^ax UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^ay UNIVERSITY OF SYDNEY   (Australia)

^az PETER MACCALLUM CANCER CENTRE   (Australia)

^ba UNIVERSITY OF MELBOURNE   (Australia)

^bb Centro de Investigacin Biomdica en Red de Enfermedades Raras   (Spain)

^bc Structural Biology and Biocomputing Programme   (Spain)

^bd HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^be HOSPITAL MONTE NARANCO   (Spain)

^bf POMERANIAN MEDICAL UNIVERSITY   (Poland)

^bg Frauenklinik der Stadtklinik Baden Baden   (Germany)

^bh STÄDTISCHES KLINIKUM KARLSRUHE   (Germany)

^bi OSLO UNIVERSITY HOSPITAL   (Norway)

^bj UNIVERSITY OF OSLO   (Norway)

^bk UNIVERSITY OF MANCHESTER   (United Kingdom)

^bl UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^bm Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^bn UNIVERSITY OF WARWICK   (United Kingdom)

^bo UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^bp UNIVERSITY OF PISA   (Italy)

^bq AMERICAN CANCER SOCIETY   (United States)

^br BRIGHAM AND WOMEN S HOSPITAL   (United States)

^bs UNIVERSITY OF MASSACHUSETTS   (United States)

^bt UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^bu INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; GENETIC MARKER;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL CYCLE ARREST; CHROMOSOME 11; CHROMOSOME 2; DNA DAMAGE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BREAST TUMOR; CAUCASIAN; CHEMISTRY; FEMALE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; MORTALITY; PROGNOSIS; SURVIVAL;

BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS;

EID: 84930015982     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv081     Document Type: Article

References (41)

1. Hartman M, Lindström L, Dickman PW, Adami HO, Hall P, Czene K. Is breast cancer prognosis inherited? Breast Cancer Res. 2007;9(3):R39.
2. Lindström L, Hall P, Hartman M, Wiklund F, Grönberg H, Czene K. Familial Concordance in Cancer Survival: A Swedish Population-based Study. Lancet Oncol. 2008;8(11):1001-1006.
3. Verkooijen HM, Hartman, M, Usel, M, Benhamou, et al. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. Int J Cancer. 2012;130(9):2103-2110.
4. Lifsted T, Le Voyer T, Williams M, et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998;77(4):640-644.
5. Michailidou K, Hall P, Gonzalez-Neira A, et al. large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-361.
6. Garcia-Closas M, Couch FJ, Lindstrom S, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392-398.
7. Shu XO, Long J, Lu W, et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res. 2012;72(5):1182-1189.
8. Azzato EM, Driver KE, Lesueur F, et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res. 2008;10(3):R47.
9. Fasching PA, Loehberg CR, Strissel PL, et al. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat. 2008;112(1):89-98.
10. Goode EL, Dunning AM, Kuschel B, et al. Effect of germline geneticvariation on breast cancer survival in a population-based study. Cancer Res. 2002;62(11):3052-3057.
11. Udler M, Azzato EM, Healey CS, et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer. 2009;125(11):2687-2696.
12. Udler M, Maia AT, Cebrian A, et al. Common germline genetic variation in antioxidant defence genes and survival after diagnosis of breast cancer. J Clin Oncol. 2007;25(21):3015-3023.
13. Hughes S, Agbaje O, Bowen RL, et al. Matrix metalloproteinase singlenucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res. 2007;13(22):6673-6680.
14. Ambrosone CB, Ahn J, Singh KK, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer. Cancer Res. 2005;65(3):1105-1111.
15. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res. 2001;61(19):7130-7135.
16. Fagerholm R, Hofstetter B, Tommiska J, et al. NAD(P)H:quinone oxidoreductase 1 NQO1∗2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet. 2008;40(7):844-853.
17. National Human Genome Research Institute. A Catalogue of Published Genome-Wide Association Studies. 2014.
18. Azzato EM, Pharoah, PDP, Harrington P, et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1140-1143.
19. Siddiq A, Couch FJ, Chen GK, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012;21(24):5373-5384.
20. Hunter DJ, Kraft P, Jacobs KB, et al. A geome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007;39(7):870-874.
21. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346-352.
22. Abraham JE, Guo Q, Dorling L, et al. Replication of Genetic Polymorphisms Reported to be Associated with Taxane-Related Sensory Neuropathy in Early Breast Cancer Patients Treated with Paclitaxel. Clin Cancer Res. 2014;20(9):2466-2475.
23. Poole CJ, Earl HM, Hiller L, et al. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. New Engl J Med. 2006;355(18):1851-1862.
24. Poole CJ, Hiller L, Howard HC, et al. tAnGo: A randomized phase III trial of gemcitabine (gem) in paclitaxel-containing, epirubicin/cyclophosphamidebased, adjuvant chemotherapy (CT) for women with early stage breast cancer (EBC). American Society of Clinical Oncology meeting. Chicago, Illinois, USA. Jun 2008. J Clin Oncol. 2008;26(15S):506.
25. Earl HM, Vallier AL, Hiller L, et al. Effects of the addition of gemcitabine, and paclitaxel-rstsequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (NeotAnGo): An open-label, 2 2 factorial randomised phase 3 trial. Lancet Oncol. 2014;15(2):201-212.
26. Einarsdóttir K, Darabi H, Li Y, et al. ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res. 2008;10(1):R15.
27. Eccles D, Gerty S, Simmonds P, et al. Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH): Study Protocol. BMC Cancer. 2007;7:160.
28. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. Am J Hum Genet. 2008;82(2):290-303.
29. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3. 2011;1(6):457-470.
30. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2012;9(2):179-181.
31. Li Y, Willer CJ, Sanna S, Abecasis GR. Genotype Imputation. Annu Rev Genomics Hum Genet. 2009;10:387-406.
32. Aulchenko YS, Ripke S, Isaacs A, van Duijn CM. GenABEL: An R library for genome-wide association analysis. Bioinformatics. 2007;23(10):1294-1296.
33. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-1558.
34. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003;327(7414):557-560.
35. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
36. Gyorffy B, Lanczky A, Eklund AC, et al. An online survival timeanalysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 2010;123(3):725-731.
37. Corradin O, Saiakhova A, Akhtar-Zaidi B, et al. Combinatorial effects of multiple enhancer variants in linkage disequilibrium dictate levels of gene expression to confer susceptibility to common traits. Genome Res. 2014;24(1):1-13.
38. Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934-947.
39. Blows FM, Driver KE, Schmidt MK, et al. Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies. PLOS Med. 2010;7(5):e1000279.
40. Norum JH, Andersen K, Sørlie T, Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy 2014. Br J Surg. 2014;101(8):925-938.
41. Li J, Lindström LS, Foo JN, et al. 2q36. 3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun. 2014;5:4051.